publication date: Feb. 7, 2020

NCI Trials

NCI Trials for Feb. 2020

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I – 10336

Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/SÈzary Syndrome

NCI Center for Cancer Research

Miljkovic, Milos

(301) 250-5216

 

Phase II – 10315

A Phase 2 Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas

Yale University Cancer Center LAO

Tesfaye, Anteneh A.

(313) 576-8637

 

Phase II – A031803

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Alliance for Clinical Trials in Oncology

Woods, Michael Edward

708-216-3155

 

Phase II – EA1181

EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)

ECOG-ACRIN Cancer Research Group

Tung, Nadine Muskatel

(617) 667-2176

 

Phase II – EA2187

A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

ECOG-ACRIN Cancer Research Group

Deming, Dustin Alan

(608) 265-1042

 

Phase II – EA6183

A Phase … Continue reading NCI Trials for Feb. 2020

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.